Eli Lilly (LLY) Total Liabilities (2009 - 2026)

Eli Lilly (LLY) has reported Total Liabilities for 18 consecutive years, with $85.4 billion the latest figure, recorded in Q1 2026.

• Total Liabilities for Q1 2026 came in at $85.4 billion, down 6.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $85.4 billion (down 6.76% YoY), and the FY2025 annual result was $85.9 billion, up 9.52% from the prior year.
• Total Liabilities was $85.4 billion for Q1 2026 at Eli Lilly, down from $85.9 billion in the prior quarter.
• Over five years, Total Liabilities peaked at $101.0 billion in Q2 2025 and troughed at $49.4 billion in Q4 2022.
• Average Total Liabilities over 5 years is $70.2 billion, with a median of $68.2 billion recorded in 2024.
• Year-over-year, Total Liabilities decreased 7.06% in 2022 and jumped 40.64% in 2025.
• Over 5 years, Total Liabilities stood at $49.4 billion in 2022, then soared by 35.67% to $67.0 billion in 2023, then increased by 17.08% to $78.5 billion in 2024, then grew by 9.52% to $85.9 billion in 2025, then retreated by 0.66% to $85.4 billion in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $85.4 billion in Q1 2026, $85.9 billion in Q4 2025, and $91.1 billion in Q3 2025.